1/6
Dr. Anthony S. Fauci Testified Before the Energy and Commerce Committee in 2018
On June 15, 2018 Dr. Anthony S. Fauci testified before the U.S. House Energy and Commerce Committee regarding preparedness in the event of biological attack, pandemics and emerging infectious disease. Here are some interesting quotes.
"NIH coordinates its biodefense research with partners in industry, academia, and the Federal Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) to ensure that promising countermeasures for biological, chemical, and radiological public health threats can proceed to advanced development. Since fiscal year 2012, NIH has supported the early development of more than 20 candidate MCMs for high-priority threats, and ultimately transitioned support for those candidate MCMs to the Biomedical Advanced Research and Development Authority (BARDA) for advanced development, with the goal of Food and Drug Administration (FDA) approval, licensure, clearance, or authorization, and for potential inclusion in the Strategic National Stockpile. NIH funding for emerging infectious disease, including biodefense, research was approximately $2.6 billion in FY 2017."
"…NIAID has supported development of broad-spectrum antiviral agents such as BCX4430 (galidesivir), which has demonstrated activity against Ebola and other RNA viruses…"
"NIAID has moved strategically toward a MCM research paradigm that features broader, more flexible platform technologies. This effort is yielding significant scientific advances that help protect against multiple emerging public health threats, whether man-made or naturally occurring. Together with academia, industry, and PHEMCE partners, NIAID remains committed to meeting public health emergency needs by advancing high-priority research toward development of MCMs for radiological/nuclear, chemical, and biological threats, including emerging and re-emerging infectious diseases."
See more of Dr. Fauci's written testimony here.
v v v
https://docs.house.gov/meetings/IF/IF02/20180615/108422/HHRG-115-IF02-Wstate-FauciA-20180615.pdf
To see Dr. Rick Bright's June 15, 2018 written testimony and other Energy and Commerce Committee documentation look here.
v v v
>>9178062 (PB)
>>9178081 (PB)
>>9178097 (PB)
>>9178127 (PB)
>>9178190 (PB)
>>9178238 (PB)
>>9178269 (PB)
>>9178296 (PB)